Article Text

Download PDFPDF
Brief psychotic disorder associated with quarantine and mild COVID-19
  1. Peter M Haddad1,2,
  2. Majid Al Abdulla2,
  3. Javed Latoo1 and
  4. Yousaf Iqbal2
  1. 1Psychiatry, Hamad Medical Corporation, Doha, Qatar
  2. 2Clinical Department, College of Medicine, QU Health, Qatar University, Doha, Qatar
  1. Correspondence to Professor Peter M Haddad; Phaddad{at}


A 30-year-old man with no significant previous or family psychiatric history became severely anxious about his health after a positive COVID-19 test. Physical symptoms of COVID-19 were mild, with no evidence of hypoxia or pneumonia, throughout his illness. He was admitted to a quarantine facility. He remained highly anxious, and 1 week later, he developed paranoid delusions and auditory hallucinations (his first psychotic episode). He was treated with lorazepam 1 mg four times a day, mirtazapine 30 mg nocte and risperidone 1 mg two times a day. His psychotic symptoms lasted 1 week. He stopped psychiatric medication after 4 weeks and had remained well when reviewed 3 months later. A Diagnostic and Statistical Manual of Mental Disorders fifth edition diagnosis of brief psychotic disorder with marked stressor (brief reactive psychosis) was made. Anxiety about his health and social isolation appeared the main aetiological factors but an inflammatory component cannot be excluded. The case highlights that first episode psychosis can be associated with mild COVID-19.

  • psychotic disorders (incl schizophrenia)
  • psychiatry (drugs and medicines)
  • COVID-19

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors PMH wrote the first draft of the manuscript. YI and JL managed the psychiatric care of the patient. All authors (PMH, MAA, JL and YI) were involved in the conception of the report, reviewed the literature, revised the article, gave approval for the final version to be published and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PMH reports personal fees from Janssen, Lundbeck, Otsuka, NewBridge Pharmaceuticals and Sunovion, outside the submitted work.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.